Protara Therapeutics, Inc. TARA 深 滬
等待開盤 03-26 09:30:00 美东时间
5.31
+0.300
+5.99%
華盛通- 最 高5.49
- 今 開5.03
- 成交量 43.55万股
- 最 低 5.03
- 昨 收 5.01
- 總市值 2.87亿
- 52周最高 7.82
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.77
- 委 比 -68.21%
- 總股本 5408.44万
- 歷史最高 800.00
- 量 比 0.30
- 振 幅 9.18%
- 歷史最低 1.04
- 每 手 1
- 風險率 1.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Protara Therapeutics GAAP EPS of -$0.37
Protara Therapeutics press release (TARA): Q4 GAAP EPS of -$0.37. As of December 31, 2025, unrestricted cash and cash equivalents and marketable debt securities totaled $197.9 million, including proce...
03-11 03:11
Protara Q4 net loss widens on higher R&D spend
Protara Q4 net loss widens on higher R&D spend Overview Biotechnology firm's Q4 net loss was $17.3 mln, driven by increased R&D expenses Company completed $86 mln public offering, cash supports operations into 2028 Outlook Protara to provide regulatory update for TARA-002 in LMs in 1H 2026 Result Dr
03-10 20:07
Protara Therapeutics Q4 EPS $(0.37) Misses $(0.33) Estimate
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.33) by 13.85 percent. This is a 22.92 percent increase over losses of $(0.48) per share
03-10 20:03
BRIEF-Protara Therapeutics Q4 EPS USD -0.37
BRIEF-Protara Therapeutics Q4 EPS USD -0.37 Mar 10 (Reuters) - Protara Therapeutics Q4 operating expenses USD 19.079 million. Q4 income from operations USD -19.079 million Q4 net income USD -17.307 million
03-10 20:00
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
JP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27
JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $27.
03-04 20:35
U.S. RESEARCH ROUNDUP-Crowdstrike, Oracle, Vulcan Materials
U.S. RESEARCH ROUNDUP-Crowdstrike, Oracle, Vulcan Materials March 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Crowdstrike, Oracle and Vulcan Materials, on Wednesday. HIGHLIGHTS * Crowdstrike CRWD.O : Bernstein rais
03-04 17:14
BUZZ-U.S. STOCKS ON THE MOVE-Domino's Pizza, FactSet, IBM
BUZZ-U.S. STOCKS ON THE MOVE-Domino's Pizza, FactSet, IBM Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks rebounded on Tuesday, led by recovering technology shares as inv
02-25 03:00
Protara's Experimental Bladder Cancer Drug Shows Encouraging Results
Protara Therapeutics (TARA) shares down after release of interim results for TARA-002 treatment of Non-Muscle Invasive Bladder Cancer.
02-24 20:41
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Vir Biotechnology (NASDAQ:VIR) shares moved upwards by 65.0% to $12.26...
02-24 20:05
